Dr. Misako Nagasaka, MD

Dr. Nagasaka practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Dr. Nagasaka's NPI, 1063707958, was assigned on June 18, 2011. Dr. Nagasaka's California license number on file is A174243.

Dr. Nagasaka's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Dr. Nagasaka's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. Dr. Nagasaka is also affiliated with Hoag Hospital Newport Beach. The medical group on file is UCI Health Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nagasaka practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Nagasaka's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Nagasaka is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Nagasaka's licenses on file in 4 states: California, Hawaii, Michigan and South Carolina.

Dmand AI lists breast cancer, colorectal cancer, fluid and electrolyte imbalances, lung cancer, prostate cancer and purpura and thrombocytopenia among the conditions Dr. Nagasaka treats.

CMS data shows 569 Medicare services from Dr. Nagasaka across 7 procedure codes in 2024, for 133 Medicare patients. Medicare paid $57,995 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 133 Medicare patients who saw Dr. Nagasaka in 2024. The largest group is 65 to 74, with 61 patients. 75% of them have cancer, and 75% have high cholesterol. 49% are also on Medicaid. Their average risk score is 3.25, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Nagasaka's median patient age at 68, with 58% women.

In 2024, Dr. Nagasaka wrote 893 Medicare Part D claims for 78 patients. 71% of them were for generic drugs. CMS names the drug for 655 of them, across 24 drugs with 11 or more claims each, at $2,780,967 in total drug cost. In 2023, CMS named 522 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Nagasaka for performance year 2024, reported through an alternative payment model (APM). Dr. Nagasaka accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Nagasaka as offering telehealth.

Dmand AI links 159 papers to Dr. Nagasaka, published from 2016 to 2025. 2022 was the busiest year, with 25. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Protein Kinase Inhibitors. Dr. Nagasaka has published most often in Lung Cancer (Auckl). Dr. Nagasaka's most frequent co-authors are Sai-Hong I I. Ou, MD, Danielle Megan Brazel, MD and Zhaohui Liao Arter, MD.

Dmand AI links Dr. Nagasaka to 3 clinical trials. 1 is still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Squamous Cell Carcinoma of Head and Neck.

CMS Open Payments shows 492 general payments to Dr. Nagasaka from 25 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 50% of the total. Janssen Pharmaceuticals, Inc paid the most, $144,425. It also lists 3 research payments totaling $1,685 from 2020 to 2024.

Dr. Nagasaka is in network with 12 carriers, including Aetna, Elevance and Health Alliance Plan. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.